Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.
Raajit K RampalMaria Pinzon-OrtizAmritha Varshini Hanasoge SomasundaraBenjamin DurhamRichard KocheBarbara SpitzerShoron MowlaAishwarya KrishnanBing LiWenbin AnAndriy DerkachSean DevlinXianhui RongTyler LongmireShira Esther EismanKeith CordnerJustin T WhitfieldGary VanasseZhu A CaoRoss L LevinePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The triple combination of ruxolitinib, LEE011, and PIM447 represents a promising therapeutic strategy with the potential to increase therapeutic responses in patients with MPN.
Keyphrases